The global facial erythema treatment market is expected to be valued at US$ 299 million by 2032, up from US$ 173.3 million in 2022, growing at a 5.1% CAGR during the forecast period.
The growing patient population, large pipeline drugs, and other factors are likely to drive up demand for facial erythema treatment. However, strict government regulations governing drug product approvals are expected to stymie global market growth.
On the contrary, increasing Research and Development activities and advancements in drug products are projected to provide manufacturers with more opportunities.
Clinic applications are expected to grow significantly during the forecast period due to rising practitioner awareness of early detection and efficient treatments that do not require any kind of invasive procedures or surgeries. Patients with mild cases, or those who are uncomfortable visiting healthcare facilities for treatment, are more likely to prefer at-home care.
| Attributes | Details |
|---|---|
| Facial Erythema Treatment Market Size (2022) | US$ 173.3 Million |
| Facial Erythema Treatment Market Size (2032) | US$ 299 Million |
| Facial Erythema Treatment Market CAGR | 5.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The steadily rising use of alcohol, cigarettes, and other narcotics may result in a variety of skin diseases. Furthermore, changing climatic conditions, the introduction of new products, and allergic reactions all contribute to skin abnormalities such as rosacea, which increases the use of facial erythema treatment.
The demand for minimally invasive procedures is increasing due to advantages such as shorter recovery time and less pain post-procedure. Furthermore, people are becoming increasingly aware of the various types of facial erythema treatment options available on the market. These are important factors that are expected to drive market growth.
People have a growing desire to improve their appearance, especially if they have skin conditions like perioral dermatitis, systemic illness, or rosacea. These, along with the need for skin cancer protection, are expected to significantly drive demand for facial erythema treatment.
Certain medications used during the treatment of facial erythema may cause side effects. Antibiotics, for example, can cause bloating, abdominal pain, loss of appetite, and other side effects. This factor is likely to limit the use of this type of treatment.
In contrast, due to varying utilization demands, key manufacturers are primarily focusing on new product solutions for specific applications. During the forecast period, these factors are expected to generate creative opportunities for market share and increase demand for facial erythema treatment.
Principal Consultant
North America is the most dominant facial erythema treatment market, accounting for 42% of total revenue. This is due to the majority of the population having fair skin and being prone to skin problems, resulting in the treatment's early adoption.
Climate changes, as well as population lifestyle changes, contribute to a variety of skin diseases. Furthermore, there has been an increase in skin treatment awareness in this region. These factors are likely to sustain the region's growing demand for facial erythema treatment and boost the global market growth.
The US government spends a lot of money on pharmaceuticals and medical devices every year, and they raise awareness in society. Furthermore, the business of the facial erythema treatment market is endorsed by the collaboration of multiple international companies with a slew of major hospital chains.
With revenue of 33.7%, Europe is the second-largest facial erythema treatment market. This is due to rising alcohol consumption and extensive research and development activities in the region.
Most cases of facial erythema, such as rosacea, have no known cause or treatment. It does, however, cause significant discomfort to those who suffer from these skin conditions. In many cases, it causes extreme embarrassment, anxiety, and depression. As a result, start-up companies are taking these issues into account and devising solutions to reduce their prevalence, fueling the growth of the facial erythema treatment market.
Dr. Wladis and Dr. Adam founded Praxis Biotechnology in response to a lack of rosacea treatment options. Praxis Biotechnology is based at Albany Medical College. Praxis Biotechnology was recently awarded $50,000 after winning FuzeHub's commercialization competition. This medication, according to the non-profit, could benefit millions of people.
Legit Health is a Spanish start-up that offers a skin diagnostic tool. The startup's software employs artificial intelligence to classify 139 skin pathologies, with a focus on the detection of seven of these, including acne, rosacea, and dermatitis. The software's algorithms automatically fill in most medical grading systems for the seven skin conditions.
The team at this UK start-up develops an evidence-based treatment and delivers it monthly. The web-based platform of the start-up assists patients in developing relationships with medical professionals and seeking expert assistance when necessary. The company also develops treatments for acne, facial erythema, anti-aging, pigmentation, and melasma.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Due to the involvement of several established players, the market share for facial erythema treatment is highly competitive. These players are focusing on expanding their presence through acquisitions, expansions, product approvals, and launches in order to capitalize on market growth opportunities.
Latest Developments:
Other Market Participants of the Facial Erythema Treatment Market:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.1% from 2022 to 2032 |
| The base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments Covered | Drug Type, Disease Type, Distribution Channel, and Region. |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia, and New Zealand |
| Country scope | United States of America; Canada; Mexico; Germany; United Kingdom; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Anacor Pharmaceuticals Inc., Astellas Pharma Inc., Galderma S.A., Meda Pharmaceuticals, Pfizer Inc., Novartis International AG, Regeneron Pharmaceuticals Inc., Sanofi S.A., Valeant Pharmaceuticals International Inc., Bausch Health Companies Inc., GlaxoSmithKline plc, Merck & Co. Inc., Enzon Pharmaceuticals, etc. |
| Customization scope | Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The facial erythema treatment market is likely to accumulate a CAGR of 5.1%, during the forecast period.
North America is the leading facial erythema treatment market with revenue of 42%.
By 2032, the facial erythema treatment market is likely to grow to a valuation of US$ 299 Million.
1. Executive Summary | Facial Erythema Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032 5.3.1. Emollients 5.3.2. Antihistamines 5.3.3. Antifungal 5.3.4. Antibiotics 5.3.5. Corticosteroids 5.3.6. Calcineurin inhibitors 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032 6. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032 6.3.1. Erythematotelangiectatic (ETR) 6.3.2. Papulopustular (PPR) 6.3.3. Phymatous 6.3.4. Ocular 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Disease Type, 2022 to 2032 7. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 8. Global Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. United States of America 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Disease Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Disease Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Disease Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Disease Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Disease Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Disease Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Type 12.2.3. By Disease Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Disease Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Disease Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Disease Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Type 14.2.3. By Disease Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Disease Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of Middle East and Africa 15.2.2. By Drug Type 15.2.3. By Disease Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Disease Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Analysis 16.1. United States of America 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Drug Type 16.1.2.2. By Disease Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Drug Type 16.2.2.2. By Disease Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Drug Type 16.3.2.2. By Disease Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Drug Type 16.4.2.2. By Disease Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Drug Type 16.5.2.2. By Disease Type 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Drug Type 16.6.2.2. By Disease Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Drug Type 16.7.2.2. By Disease Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Drug Type 16.8.2.2. By Disease Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Drug Type 16.9.2.2. By Disease Type 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Drug Type 16.10.2.2. By Disease Type 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Drug Type 16.11.2.2. By Disease Type 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Drug Type 16.12.2.2. By Disease Type 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Drug Type 16.13.2.2. By Disease Type 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Drug Type 16.14.2.2. By Disease Type 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Drug Type 16.15.2.2. By Disease Type 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Drug Type 16.16.2.2. By Disease Type 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Drug Type 16.17.2.2. By Disease Type 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Drug Type 16.18.2.2. By Disease Type 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Drug Type 16.19.2.2. By Disease Type 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Drug Type 16.20.2.2. By Disease Type 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Drug Type 16.21.2.2. By Disease Type 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Disease Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Anacor Pharmaceuticals Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Astellas Pharma Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Galderma S.A. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Meda Pharmaceuticals 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis International AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Pfizer Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Regeneron Pharmaceuticals Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Sanofi S.A. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Valeant Pharmaceuticals International, Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Merck and Co. Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Facial Erythema Treatment Market
